T Regulatory Cell-Associated Tolerance Induction by High-Dose Immunoglobulins in an HLA-Transgenic Mouse Model of Pemphigus
Cells · 2023
DOI: 10.3390/cells12091340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Christoph Hudemann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, Philipps-University Marburg, 35037 Marburg, Germany. Hauptthemen laut MEDLINE: Pemphigus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotest Pharma AG, Deutsche Forschungsgemeinschaft (DFG).
Abstract (Originalsprache)
Pemphigus vulgaris (PV) is a potentially lethal autoimmune bullous skin disorder caused by IgG autoantibodies against desmoglein 3 (Dsg3) and Dsg1. During the last three decades, high-dose intravenous immunoglobulins (IVIgs) have been applied as an effective and relatively safe treatment regime in severe, therapy-refractory PV. This prompted us to study T- and B- cell polarization by IVIg in a human-Dsg3-dependent mouse model for PV. Using humanized mice transgenic for HLA-DRB1*04:02, which is a highly prevalent haplotype in PV, we employed IVIg in two different experimental approaches: in prevention and quasi-therapeutic settings. Our data show that intraperitoneally applied IVIg was systemically distributed for up to 42 days or longer. IVIg-treated Dsg3-immunized mice exhibited, in contrast to Dsg3-immunized mice without IVIg, significantly less Dsg3-specific IgG, and showed induction of T regulatory cells in lymphatic tissue. Ex vivo splenocyte analysis upon Dsg3-specific stimulation revealed an initial, temporarily reduced antigen-induced cell proliferation, as well as IFN-γ secretion that became less apparent over the course of time. Marginal-zone B cells were initially reduced in the preventive approach but re-expanded over time. In contrast, in the quasi-therapeutic approach, a robust down-regulation in both spleen and lymph nodes was observed. We found a significant down-regulation of the immature transitional 1 (T1) B cells in IVIg-treated mice in the quasi-therapeutic approach, while T2 and T3, representing a healthy stage of B-cell development, appeared to be up-regulated by IVIg. In summary, in two experimental settings employing an active PV mouse model, we demonstrate distinct alterations of T- and B-cell populations upon IVIg treatment, compatible with a tolerance-associated polarization in lymphatic tissue. Our data suggest that the clinical efficacy of IVIg is at least modulated by distinct alterations of T- and B-cell populations compatible with a tolerance-associated polarization in lymphatic tissue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, Philipps-University Marburg, 35037 Marburg, Germany.
- Department of Dermatology, University of Heidelberg, 69117 Heidelberg, Germany.
- Department of Dermatology, University of Lübeck, 23562 Lübeck, Germany.
- Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, 23562 Lübeck, Germany.
- Department of Dermatology, Venerology and Allergology, German Armed Forces Central Hospital Koblenz, 56072 Koblenz, Germany.
ORCID-Profile: Christoph Hudemann
Förderung
- Biotest Pharma AG
- Deutsche Forschungsgemeinschaft (DFG)
Zitieren
APA
Hudemann, C., Hoffmann, J., Schmidt, E., Hertl, M., & Eming, R. (2023). T Regulatory Cell-Associated Tolerance Induction by High-Dose Immunoglobulins in an HLA-Transgenic Mouse Model of Pemphigus. Cells. https://doi.org/10.3390/cells12091340
Vancouver
Hudemann C, Hoffmann J, Schmidt E, Hertl M, Eming R. T Regulatory Cell-Associated Tolerance Induction by High-Dose Immunoglobulins in an HLA-Transgenic Mouse Model of Pemphigus. Cells. 2023. doi:10.3390/cells12091340
BibTeX
@article{Hudemann2023,
author = {Hudemann, Christoph and Hoffmann, Jochen and Schmidt, Enno and Hertl, Michael and Eming, Rüdiger},
title = {T Regulatory Cell-Associated Tolerance Induction by High-Dose Immunoglobulins in an HLA-Transgenic Mouse Model of Pemphigus},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12091340}
}
EUVIMED